A Phase I clinical trial in patients with glioblastoma using the combination of Ad-RTS-IL-12 (INXN-2001) and veledimex and a selected checkpoint inhibitor
Phase of Trial: Phase I
Latest Information Update: 16 Feb 2017
At a glance
- Drugs INXN 2001 (Primary) ; Veledimex (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors ZIOPHARM Oncology
- 16 Feb 2017 According to a ZIOPHARM Oncology media release, the company expects to initiate this study during the first half of 2017.
- 01 Mar 2016 New trial record
- 24 Feb 2016 The company expects to begin this trial in 2016, according to a Ziopharm media release.